Acquired Company

Graybug Vision, Inc. merged with CalciMedica to form the combined company CalciMedica, Inc.; the merger closed March 20, 2023, and CalciMedica common stock began trading on Nasdaq under CALC on March 21, 2023.

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops Auxora for the treatment of acute ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory indications. The company is based in La Jolla, California. Show more

Location: 505 COAST BOULEVARD SOUTH, LA JOLLA, CA, UNITED STATES, 92037, La Jolla, CA, 92037, USA | Website: https://calcimedica.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

12.97M

52 Wk Range

$0.82 - $7.20

Previous Close

$1.02

Open

$0.98

Volume

1,965,368

Day Range

$0.85 - $1.02

Enterprise Value

9.514M

Cash

5.47M

Avg Qtr Burn

-4.778M

Insider Ownership

23.62%

Institutional Own.

55.98%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Auxora™ Details Acute Pancreatitis	Phase 2b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Auxora™ Details Asparaginase-induced pancreatic toxicity	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Auxora™ Details Acute Kidney Injury (AKI)	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GB-102 (Pan-VEGF inhibitor) Details Eye disease , Wet age-related macular degeneration , Age-related macular degeneration	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GB-102 (Pan-VEGF inhibitor) Details Diabetes, Eye disease , Diabetic macular edema	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.